ERBB2 and bladder transitional cell carcinoma: Recent works have evaluated HER2 status in urothelial bladder cancer (UBC) in order to assess the therapeutic potential of this target, demonstrating significant protein overexpression (score 2+ or 3+) or gene amplification in approximately 10 % of the tumors [11–15].